Loading stock data…
TScan Therapeutics (TCRX)
$0.34-0.05 (-11.93%)
Market ClosedLast close Sep 8
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TScan Therapeutics, Inc. in the Healthcare sector is trading at $0.34 with a market capitalization of $59M. Wall Street consensus targets $2.67 (3 analysts), implying a +673.4% move over the next 12 months. The stock is currently near its 52-week low of $0.33, remaining 65.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 11 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +673.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 11) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $982,000↓ | $2.57M↑ | $2.51M↓ | $3.08M↑ | $2.17M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$29.14M↓ | -$23.86M↑ | -$37.05M↑ | -$38.65M↓ | -$36.25M |
| Net Income | -$28.67M↓ | -$22.98M↑ | -$35.71M↑ | -$36.95M↓ | -$34.13M |
Peer Comparison
JNJUNHPFE
Fundamentals
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$58.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-128.25%
Volume
Today's trading volume
1.53M
Recent News
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program
TScan Therapeutics (NASDAQ:TCRX) announced a strategic reorganization that includes a workforce reduction of approximately 75% as the company redirects resources toward an in vivo-engineered T cell receptor, or TCR-T, program targeting solid tumors. The Waltham, Massachusetts-based company plans to advance two product candidates into investigational new drug-enabling studies.
Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?
Amgen (NasdaqGS:AMGN) has elected to terminate its research collaboration and license agreement with TScan Therapeutics focused on Crohn's disease target discovery. The decision ends Amgen's exclusive effort with TScan to identify and develop T-cell antigen targets for Crohn's disease. This change may affect Amgen's research pipeline in inflammatory bowel disease and influence its future approach to biotech partnerships. For broader context on the sector, consider exploring other...
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.69% and -61.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of 0.00% and -73.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?